Effects of a Long Term Dietary Portfolio and of Sequential Removal of Food Components From the Diet

Sponsor
University of Toronto (Other)
Overall Status
Completed
CT.gov ID
NCT00438893
Collaborator
Canada Research Chairs Endowment of the Federal Government of Canada (Other), Natural Sciences and Engineering Research Council, Canada (Other), Loblaw Companies Limited (Industry), Almond Board of California (Other), Unilever R&D (Industry)
66
1
1
68
1

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the long term effectiveness of the dietary portfolio, consisting of viscous fibers, soy products, nuts and plant sterols, as well as the effects of removing single food components from the dietary portfolio on cholesterol reduction and other cardiovascular risk factors.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Dietary portfolio of cholesterol-lowering foods
N/A

Detailed Description

We have shown in 1-month metabolic studies that a dietary portfolio, consisting of soy products, viscous fibers, almonds and plant sterols in the form of margarine, can lower cholesterol to the same extent as first generation statins (cholesterol-lowering drugs). However, the long-term effectiveness of the dietary portfolio is not known. Furthermore, it is not known to what extent each of the food components contribute to the cholesterol reductions observed. We wish to therefore evaluate the long term effects of the dietary portfolio as well as the effects of removing single food components from the dietary portfolio on cholesterol reduction and other cardiovascular risk factors. We believe the removal of single food components will result in a reduction of the cholesterol-lowering effect to a similar extent as predicted with the cholesterol reductions observed when the food component is consumed alone.

Method:

66 subjects will be recruited for a 6-month to 5 year long-term dietary portfolio study with the option for continuation (re-consenting) at the end of 6, 12 or 24 months. The active dietary components consist of viscous fibers (including oat bran), soy products (including soy milk), almonds and plant sterols (sterol-enriched margarine). Lipids, blood pressure, body weight, and routine biochemical and hematology analyses will be performed over the 5 year period, with lipids and blood pressure measured at 2 monthly intervals. 40-50 subjects on the long term dietary portfolio study, all of whom will have been on the diet for at least 1 year, will be asked to remove a specific food component from their regular dietary portfolio for a 10 week period. After the 10 week period, subjects will be asked return to the normal dietary portfolio with all food components consumed and continue on the long-term dietary portfolio.

Bloods will be taken at weeks 0, 6 and 10 of the food component removal period; and at 2-monthly intervals for 20 weeks prior to and after the 10 week period while on the long-term dietary portfolio with all food components.

Study Design

Study Type:
Interventional
Actual Enrollment :
66 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Long-Term Effect of Viscous Fibers, Soy Protein, and Plant Sterol Foods in Combination on Serum Cholesterol and Other Risk Factors for Cardiovascular Disease
Actual Study Start Date :
Sep 1, 2003
Actual Primary Completion Date :
May 1, 2009
Actual Study Completion Date :
May 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Other: A portfolio of cholesterol-lowering foods

Dietary advice to consume a dietary portfolio of cholesterol-lowering foods

Dietary Supplement: Dietary portfolio of cholesterol-lowering foods
A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)

Outcome Measures

Primary Outcome Measures

  1. Total cholesterol [At weeks 0, 2,4, 8,12, 18, 24, 34, 44, 52; then every 2 months to a total of 5 years]

  2. LDL cholesterol [At weeks 0, 2,4, 8,12, 18, 24, 34, 44, 52; then every 2 months to a total of 5 years]

  3. C-reactive protein [At weeks 0, 12, 24, 34, 52; then every 6 months to a total of 5 years]

  4. Blood pressure [At weeks 0, 2,4, 8,12, 18, 24, 34, 44, 52; then every 2 months to a total of 5 years]

Secondary Outcome Measures

  1. Body Weight [At weeks 0, 2,4, 8,12, 18, 24, 34, 44, 52; then every 2 months to a total of 5 years]

  2. Apolipoprotein A1 and B [At weeks 0, 2,4, 8,12, 18, 24, 34, 44, 52; then every 2 months to a total of 5 years]

  3. Lp(a) [At weeks 0, 24, 52; then every 6 months to a total of 5 years]

  4. Routine Biochemistry and hematology measurements [At week 0, 12, 24 and every 6 months to 5 years]

  5. Compliance to dietary portfolio components [At years, 1, 2, 3, 4 and 5]

  6. 24 hour urinary markers and electrolytes (optional) [At week 0 and end of years 1, 2, 3, 4 and 5]

  7. Oxidative stress markers [week 0 and every 6 months to 5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy adult men and postmenopausal women currently enrolled in the long-term portfolio study

  • Body mass index <32 kg/m2

  • Constant body weight over last 6 months preceding the onset of the study

  • Fasting LDL-cholesterol concentration >4.1 mmol/L at diagnosis

Exclusion Criteria:
  • women of child-bearing potential

  • major cardiovascular event (stroke or myocardial infarction)

  • positive molecular diagnosis of familial hypercholesterolemia

  • secondary causes of hypercholesterolemia (hypothyroidism, unless treated & on a stable dose of L-thyroxine, renal or liver disease)

  • use of cholesterol-lowering medications

  • serum triglycerides >4.5 mmol/L

  • blood pressure > 145/90 mmHg

  • diabetes and/or major disorders such as liver disease, renal failure or cancer

  • major surgery <6 months prior to randomization

  • alcohol consumption >2 drinks per day

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre Toronto Ontario Canada M5C 2T2

Sponsors and Collaborators

  • University of Toronto
  • Canada Research Chairs Endowment of the Federal Government of Canada
  • Natural Sciences and Engineering Research Council, Canada
  • Loblaw Companies Limited
  • Almond Board of California
  • Unilever R&D

Investigators

  • Principal Investigator: David JA Jenkins, MD, PhD, DSc, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
David Jenkins, Principle Investigator, University of Toronto
ClinicalTrials.gov Identifier:
NCT00438893
Other Study ID Numbers:
  • REB 03-043
  • HC-CT#100934
First Posted:
Feb 22, 2007
Last Update Posted:
Oct 15, 2018
Last Verified:
Oct 1, 2018
Keywords provided by David Jenkins, Principle Investigator, University of Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 15, 2018